Meds. Co. v. Hospira, Inc., Nos. 2014-1469, 2014-1504, (Fed. Cir. Feb. 6, 2018) (Before Dyk, Wallach, and Hughes, J.) (Opinion for the court, Hughes, J.).
The Medicines Company owns patents ‘727 and ‘343, which cover an improved process for manufacturing a bivalirudin product, marketed as Angiomax. The improved mixing method covered by the patents was incorporated into the company’s master batch record on October 25, 2006 and used by Ben Venue Laboratories, a contract manufacturer, on all Angiomax batches since October 31, 2006. On February 27, 2007, The Medicines Company entered into a Distribution Agreement with Integrated Commercialization Solutions, Inc. (ICS). On July 27, 2008, The Medicines Company filed the ‘727 and ‘343 patent applications.
Hospira, submitted an Abbreviated New Drug Application (“ANDA”) to the Food and Drug Administration (“FDA”) to market generic Angiomax, The Medicines Company sued Hospira for infringement of the ‘727 and ‘343 patents under 35 U.S.C. § 271(e)(2). Hospira asserted patent invalidity. The district court held that the patents were neither invalid nor infringed, and both parties appealed.
The Federal Circuit affirmed the court’s finding of non-infringement. It reversed the finding that the Distribution Agreement between The Medicines Company and ICS was not a commercial offer for sale, for the purposes of the on-sale bar, and remanded for a determination of whether this offer covered the patented invention.
First, Hospira did not infringe the patented method because its mixing process did not satisfy the “efficient mixing” limitation of the ‘727 and ‘343 patents. Rather than adding the pH-adjusting solution at a controlled rate and using both a paddle mixer and homogenizer, as required by the claims, Hospira added the solution in three portions using a single mixer.
Second, under the on-sale bar, a patent is invalid if, before the critical date: (1) the product is the subject of a commercial offer for sale, and (2) the invention is ready for patenting. Pfaff v. Wells. Elecs., Inc., 525 U.S. 55, 67 (1998). The Uniform Commercial Code (UCC), while not dispositive, is a useful guide for determining if a commercial offer for sale was made. Here, the Distribution Agreement between Medicines Company and ICS established a commercial offer for sale, by providing:
- That The Medicines Company desired to sell the product to ICS and ICS desired to purchase and distribute the product;
- The price of the product;
- The purchase schedule; and
- That title would pass from The Medicines Company to ICS.
The term allowing The Medicines Company to reject submitted purchase forms did not defeat this from being considered an offer for sale within the meaning of 35 U.S.C. § 102. This was true because the Agreement required The Medicines Company to use commercially reasonable efforts to fill the purchase orders. Additionally, because The Medicines Company derived the majority of its revenue from Angiomax sales, a rejection of an order was unlikely.
The Federal Circuit reiterated that the on-sale bar does not exempt commercial agreements between a patentee and its supplier or distributor. It is the commercial character of the transaction that is more relevant than the parties involved when assessing whether there was a commercial offer for sale.
For the on-sale bar to apply, the invention as defined by the patent claims must be on sale. The Court remanded for a determination of whether the Distribution Agreement offered for sale the Angiomax product created by the improved mixing process claimed by the ‘727 and ‘343 patents.
Finally, the Court affirmed the district court’s holding that the invention was ready for patenting before the critical date. An invention is ready for patenting when it is reduced to practice or is “depicted in drawings or described in writings of sufficient nature to enable a person of ordinary skill in the art to practice the invention.” Hamilton Beach Brands, Inc. v. Sunbeam Prods., Inc., 726 F.3d 1370, 1375 (Fed. Cir. 2013). Here, Ben Venue reduced the invention to practice by producing batches of Angiomax using the patented process by following the master batch record which disclosed how to do so.
A distribution agreement between a patentee and its supplier or distributor may constitute a commercial offer for sale for the purposes of the on-sale bar even the agreement does not specifically dictate the amount of product to be sold. Including the product price, purchase schedule, and terms that establish a transfer of title are sufficient to constitute a commercial offer for sale if the agreement actually covers the patented invention.
About Troutman Sanders and the Federal Circuit Review
Founded in 1897, Troutman Sanders LLP is an international law firm with more than 650 lawyers practicing in 16 offices located throughout the United States and Asia. Each week, partners Joe Robinson and Bob Schaffer, succinctly summarize the preceding week of Federal Circuit precedential patent opinions. They provide the pertinent facts, issues, and holdings. This Review allows you to keep abreast of the Federal Circuit’s activities – important for everyone concerned with intellectual property. IPWatchdog.com is pleased to publish these summaries each week.